港股異動 | 和鉑醫藥-B再度飆升逾19% 子公司與國內ADC領域龍頭科倫博泰達成合作
格隆匯12月29日丨和鉑醫藥-B再度飆升逾19%,報2.98港元創近四個月新高,近三日累計漲幅達64%,最新總市值23億港元。12月23日午後,和鉑醫藥發佈公吿,宣佈旗下全資子公司諾納生物與國內ADC領域龍頭企業科倫博泰就抗體藥物偶聯物(ADC)的合作簽署了兩項補充協議。雙方一致同意將共同開發的兩款ADC產品許可給被許可第三方,諾納生物有權獲得兩款相關產品首付款、里程碑付款和分級特許權使用費的30%。其中產品1的預付款為3000萬美元,諾納生物所得為900萬美元。除了與科倫的合作之外,自2022年11月公司宣佈成立諾納生物起,已接連與ModernaTX、Dragonfly Therapeutics等全球頭部藥企開展合作。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.